4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma

Background

Lipiodol transcatheter arterial chemoembolization (TACE) , known as c-TACE , is widely used to treat hepatocellular carcinoma (HCC). Recently, a drug-eluting bead (DEB) has been developed to sustain continual drug delivery to the tumor. We evaluate the efficacy and safety of TACE with doxorubicin-loaded drug eluting beads (D-TACE) in this study.

Methods

This retrospective study included 228 unresectable HCC patients who received cTACE (n = 153) or D-TACE(n = 75) in Zhongshan hospital, Fudan University from September 2018 to February 2019. Tumor response were evaluated by MRI according mRECIST one month after treatment, and adverse events were recorded as well.

Results

The disease control rate(DCR) of D-TACE was 78.6% versus 49.3% of c-TACE(p = 0.03),which demonstrated D-TACE had the better tumor reponse. There were no treatment related major complications in all patients, and no statistically significant difference in postembolization syndrome , liver toxicity and hematological toxicity between two groups(p > 0.05). Subgroup analyses indicated that patients with tumor size less than 7cm and tumor numbers less than 3 favored D-TACE , while there was no significant difference in efficacy in the patients with tumor size greater than 10cm (P > 0.05).

Conclusions

In unresectable HCC, transcatheter treatment with DEB loaded with doxorubicin offers a better objective tumor response than conventional TACE, especially in patients with tumor size less than 7cm and tumor numbers less than 3.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.